90 related articles for article (PubMed ID: 36119069)
1. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.
Zhong K; Xu Y; Cheng Y; Wen Y; Cai L; He G; Huang H; Fu S; Zhong X; Zheng Y; Chen T; Huang M; Pan M
Front Immunol; 2022; 13():999763. PubMed ID: 36119069
[TBL] [Abstract][Full Text] [Related]
2. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
[TBL] [Abstract][Full Text] [Related]
3. Prolonged response to Tyrosine Kinase Inhibitors followed by Immunotherapy in metastatic hepatocellular carcinoma: A rare case report.
Roy P; Parthasarathy KM
J Cancer Res Ther; 2023; 19(5):1457-1461. PubMed ID: 37787330
[TBL] [Abstract][Full Text] [Related]
4. Identification of key molecules in the formation of portal vein tumor thrombus in hepatocellular carcinoma based on single cell transcriptomics and
Zhang M; Su C; Liu X; Hu S; Yan X
Transl Cancer Res; 2024 Apr; 13(4):1737-1761. PubMed ID: 38737676
[TBL] [Abstract][Full Text] [Related]
5. Triplet regimen as a novel modality for advanced unresectable hepatocellular carcinoma: A case report and review of literature.
Zhao Y; He GS; Li G
World J Clin Cases; 2023 Sep; 11(27):6558-6564. PubMed ID: 37900216
[TBL] [Abstract][Full Text] [Related]
6. Complete spontaneous necrosis of hepatocellular carcinoma accompanied by portal vein tumor thrombosis: A case report.
Goto Y; Uchino Y; Sasaki S; Shirahama N; Nomura Y; Akiba J; Ishikawa H; Akagi Y; Tanaka H; Okuda K
Int J Surg Case Rep; 2018; 44():220-225. PubMed ID: 29544184
[TBL] [Abstract][Full Text] [Related]
7. Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma.
Lim CJ; Chew V
Semin Liver Dis; 2020 May; 40(2):131-142. PubMed ID: 31810095
[TBL] [Abstract][Full Text] [Related]
8. The enrichment of the gut microbiota Lachnoclostridium is associated with the presence of intratumoral tertiary lymphoid structures in hepatocellular carcinoma.
Zhao R; Li J; Chen B; Zhao J; Hu L; Huang K; Chen Q; Yao J; Lin G; Bao L; Lu M; Wang Y; Chen G; Wu F
Front Immunol; 2023; 14():1289753. PubMed ID: 38116013
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the tumour immune microenvironment of hepatocellular carcinoma.
Liu S; Jia M; Dai R
Scand J Immunol; 2023 Nov; 98(5):e13327. PubMed ID: 38441331
[TBL] [Abstract][Full Text] [Related]
10. The immune response of hepatocellular carcinoma after locoregional and systemic therapies: The available combination option for immunotherapy.
Duan Y; Zhang H; Tan T; Ye W; Yin K; Yu Y; Kang M; Yang J; Liao R
Biosci Trends; 2024 Jan; 17(6):427-444. PubMed ID: 37981319
[TBL] [Abstract][Full Text] [Related]
11. Effect of surface modification on the distribution of magnetic nanorings in hepatocellular carcinoma and immune cells.
Jiao W; Wen N; Wang S; Zhou G; Lu Q; Su Z; Wang X; Hu S; Xie Y; Zhang N; Liu X
J Mater Chem B; 2024 Mar; 12(10):2628-2638. PubMed ID: 38376513
[TBL] [Abstract][Full Text] [Related]
12. The Era of Immunotherapy in Hepatocellular Carcinoma: The New Mission and Challenges of Magnetic Resonance Imaging.
Chen Y; Yang C; Sheng L; Jiang H; Song B
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835371
[TBL] [Abstract][Full Text] [Related]
13. Evaluating the risk-benefit ratio of immunotherapy according to liver-functional reserve in advanced HCC: the dark side of the moon.
Cabibbo G; Celsa C; Alimenti E; Iavarone M
Hepatology; 2023 Apr; 77(4):1074-1077. PubMed ID: 36626617
[No Abstract] [Full Text] [Related]
14. Tumor Immune Microenvironment as a New Therapeutic Target for Hepatocellular Carcinoma Development.
Kim E
Dev Reprod; 2023 Dec; 27(4):167-174. PubMed ID: 38292233
[TBL] [Abstract][Full Text] [Related]
15. Lipids link immune suppression to effective immunotherapy in steatotic hepatocellular carcinoma.
Li B; Sauter ER
Ann Transl Med; 2023 Mar; 11(5):226. PubMed ID: 37007550
[No Abstract] [Full Text] [Related]
16. Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.
Kudo M
Liver Cancer; 2023 Sep; 12(4):289-296. PubMed ID: 37901198
[No Abstract] [Full Text] [Related]
17. The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.
Liu Y; Liu Z; Yang Y; Cui J; Sun J; Liu Y
Br J Cancer; 2023 Oct; 129(7):1041-1049. PubMed ID: 37452117
[TBL] [Abstract][Full Text] [Related]
18. New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.
Gordan JD; Keenan BP; Lim HC; Yarchoan M; Kelley RK
Drugs; 2023 Aug; 83(12):1091-1109. PubMed ID: 37402062
[TBL] [Abstract][Full Text] [Related]
19. Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma.
Koh B; Tan DJH; Lim WH; Wong JSL; Ng CH; Chan KE; Wang M; Yong WP; Dan YY; Wang LZ; Tan N; Muthiah M; Kow A; Syn NL; Huang DQ; Yau T
Oncoimmunology; 2023; 12(1):2214478. PubMed ID: 37284696
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer.
He M; He Q; Cai X; Liu J; Deng H; Li F; Zhong R; Lu Y; Peng H; Wu X; Chen Z; Lao S; Li C; Li J; He J; Liang W
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
